Esperion Therapeutics Clears Key Antitrust Hurdle for Acquisition by Archimed
ESPR has more than doubled off its 52-week low of $0.949.
Summary
Esperion Therapeutics announced that a key antitrust waiting period for its acquisition by Archimed has expired, clearing a major regulatory hurdle for the deal.
Key Events · M&A and Partnerships · ESPR
-
HSR Waiting Period Expired
The Hart-Scott-Rodino Antitrust Improvements Act waiting period for the proposed merger expired at 11:59 p.m. Eastern Time on June 15, 2026.
-
Key Regulatory Condition Met
This expiration satisfies a significant regulatory condition for the previously announced acquisition of Esperion Therapeutics by Essence Parent Inc., an affiliate of ArchiMed SAS.
-
Merger Progresses Towards Close
The clearance of this antitrust hurdle brings the acquisition closer to completion, following the definitive agreement announced on May 1, 2026.
-
Remaining Condition: Shareholder Vote
The merger remains subject to other customary closing conditions, including adoption of the Merger Agreement by the Company's stockholders at a special meeting scheduled for July 8, 2026.
Analysis · ESPR · Life Sciences
Esperion Therapeutics announced the expiration of the Hart-Scott-Rodino (HSR) Antitrust Improvements Act waiting period, a critical regulatory milestone for its pending acquisition by Essence Parent Inc., an affiliate of Archimed SAS. This development significantly de-risks the transaction, moving it closer to completion. The merger, valued at $3.16 per share plus CVRs, still requires stockholder approval at a special meeting scheduled for July 8, 2026.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 40.1% of the 367 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ESPR was trading at $3.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $814.3M. The 52-week trading range was $0.95 to $4.18. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.